Economic burden of patients with inoperable advanced breast cancer receiving early or late capecitabine or trastuzumab as second-line treatment: A population-based study

Chieh-Yu Liu


This study aimed to investigate the economic burden and healthcare resource utilization of receiving early or late capecitabine and trastuzumab as second-line anthracycline- or taxane-based treatments for inoperable advanced breast cancer (IABC). Data was retrieved from the National Health Insurance Research Database of Taiwan. The demographic characteristics, healthcare resource utilization, and economic burden of patients with IABC receiving capecitabine and trastuzumab for 0–3, 3–6, 6–9 and 9–12 months after anthracycline- or taxane-based treatments were analyzed. 1,629 women newly diagnosed with IABC were recruited. IABC incidence rates reduced from 9.75% in 2004 to 7.35% in 2006. However, the proportion of patients receiving capecitabine or trastuzumab after anthracycline- or taxane-based treatments increased. Inpatient admissions (times/year), length of hospital stay (days/year), and outpatient visits (visits/year) did not differ significantly for the 2004–2005, 2005–2006 and 2006–2007 cohorts of patients with IABC receiving capecitabine and trastuzumab at different time points. The 1-year healthcare cost and outpatient, inpatient, and total costs (USD/year) differed significantly for trastuzumab but not for capecitabine. The conclusion indicated that early or late capecitabine or trastuzumab administration after first-line anthracycline or taxane-based treatments did not exhibit a change in healthcare resource utilization. In addition, the 1-year healthcare costs did not differ significantly for patients with IABC receiving early or late capecitabine. However, patients with IABC receiving trastuzumab continue to face an economic burden.


Inoperable breast cancer; capecitabine; trastuzumab; healthcare resources; economic burden

Full Text:



The Medical Letter: Capecitabine and trastuzumab for metastatic breast cancer. Med Lett Drugs Ther 1998; 40(1039): 106–108.

Ershler WB. Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11(4): 325–335. doi: 10.1634/theoncologist.11-4-325

Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology 1998; 12 (Suppl 7): 39–43.

Smorenburg CH, Bontenbal M, Verweij J. Capecitabine in breast cancer: Current status. Clin Breast Cancer 2001; 1(4): 288–293. doi: 10.3816/CBC.2001.n.003

Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014; 40(2): 259–270. doi: 10.1016/j.ctrv.2013.09.002

Verma S, Joy AA, Rayson D, et al. HER Story: The next chapter in HER-2-directed therapy for advanced breast cancer. Oncologist 2013; 18(11): 1153– 1166. doi: 10.1634/theoncologist.2013-0217

Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 2000; 27(6 Suppl 11): 38–45; discussion 92–100.

Max W, Sung HY, Stark B. The economic burden of breast cancer in California. Breast Cancer Res Treat 2009; 116(1): 201–207. doi: 10.1007/s10549-008-0149-4

Montero AJ, Eapen S, Gorin B, et al. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat 2012; 134(2): 815–822. doi: 10.1007/s10549-012-2097-2

Foster TS, Miller JD, Boye ME, et al. The econom-ic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev 2011; 37(6): 405–415.

Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008; 109(2): 367–377. doi: 10.1007/s10549-007-9650-4

Lee SG, Jee YG, Chung HC, et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclo-phosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat 2009; 114(3): 589–595. doi: 10.1007/s10549-008-0035-0

Okubo I, Kondo M, Toi M, et al. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Gan To Kagaku Ryoho 2005; 32(3): 351–363.

Lilliu H, Stevens D, Brun C, et al. Cost of treatment and follow up of breast cancer: A retrospective assessment in a comprehensive cancer centre. Bull Cancer 2002; 89(6): 635–642.

Armstrong DK, Fetting JH, Davidson NE, et al. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993; 28(3): 277–284. doi: 10.1007/BF00666589

Cooper BW, Radivoyevitch T, Overmoyer BA, et al. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 2006; 97(3): 311–318. doi: 10.1007/s10549-005-9125-4

Lang HC, Wu SL. Lifetime costs of the top five cancers in Taiwan. Eur J Health Econ 2012; 13(3): 347–353. doi: 10.1007/s10198-011-0307-1

Boswell KA, Wang X, Shah MV, et al. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature. Breast 2012; 21(6): 701–706. doi: 10.1016/j.breast.2012.09.005

Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: A literature-based model analysis of costs in the Italian National Health Service. Clin Ther 2004; 26(9): 1546–1561. doi: 10.1016/j.clinthera.2004.09.014

Simon MS, Ibrahim D, Newman L, et al. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 2002; 19(6): 453–463. doi: 10.2165/00002512-200219060-00004

Qi WX, Tang LN, He AN, et al. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: A meta-analysis of four phase III trials. Breast 2013; 22(3): 314–319. doi: 10.1016/j.breast.2012.07.014

Feng QJ, Zhang F, Huang XY, et al. Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis. Pathol Oncol Res 2014; 20(1): 179–184. doi: 10.1007/s12253-013-9681-6

Chitapanarux I, Kamnerdsupaphon P, Tharavichitkul E, et al. Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer. Asia Pac J Clin Oncol 2012; 8(1): 76–82. doi: 10.1111/j.1743-7563.2011.01467.x

Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29(34): 4498– 4504. doi: 10.1200/JCO.2010.33.9101

Zhu Q, DeFusco PA, Ricci AJ, et al. Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography. Radiology 2013; 266(2): 433–442. doi: 10.1148/radiol.12112415

Nichols L, Barton PL, Glazner J, et al. Diabetes, minor depression and health care utilization and expenditures: a retrospective database study. Cost Eff Resour Alloc 2007; 5: 4. doi: 10.1186/1478-7547-5-4

Ai C, Norton EC. Standard errors for the retransformation problem with heteroscedasticity. J Health Econ 2000; 19(5): 697–718. doi: 10.1016/S0167-6296(00)00046-1

Chuwa EW, Yeo AW, Koong HN, et al. Early detection of breast cancer through population-based mammographic screening in Asian women: A comparison study between screen-detected and symptomatic breast cancers. Breast J 2009; 15(2): 133–139. doi: 10.1111/j.1524-4741.2009.00687.x

Miller AB. Practical applications for clinical breast examination (CBE) and breast self-examination (BSE) in screening and early detection of breast cancer. Breast Care (Basel) 2008; 3(1): 17–20. doi: 10.1159/000113934

Chu PC, Hwang JS, Wang JD, et al. Estimation of the financial burden to the National Health Insurance for patients with major cancers in Taiwan. J Formos Med Assoc 2008; 107(1): 54–63. doi: 10.1016/S0929-6646(08)60008-X

Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33(6): 594–601. doi: 10.1200/JCO.2013.52.4892

Halim A, Wahba H. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC. Med Oncol 2012; 29(2): 454–458. doi: 10.1007/s12032-011-9868-1

Li H, Huang Y, Huang R, et al. Standard treatment cost of female breast cancer at different TNM stages. Chin J Oncol 2013; 35(12): 946–950.



  • There are currently no refbacks.

Copyright (c) 2018 Chieh-Yu Liu

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.